Noden Pharma Drug Patent Portfolio
Noden Pharma owns 3 orange book drugs protected by 18 US patents Given below is the list of Noden Pharma's drug patents along with their expiration dates.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US10016407 | Pharmaceutical compositions and methods of using the same | 07 Feb, 2037 | Active |
US10149843 | Pharmaceutical compositions and methods of using the same | 07 Feb, 2037 | Active |
US10231961 | Pharmaceutical compositions and methods of using the same | 07 Feb, 2037 | Active |
US10413505 | Pharmaceutical compositions and methods of using the same | 07 Feb, 2037 | Active |
US10420760 | Pharmaceutical compositions and methods of using the same | 07 Feb, 2037 | Active |
US10857095 | Pharmaceutical compositions and methods of using the same | 07 Feb, 2037 | Active |
US10894012 | Pharmaceutical compositions and methods of using the same | 07 Feb, 2037 | Active |
US10933060 | Pharmaceutical compositions and methods of using the same | 07 Feb, 2037 | Active |
US10973811 | Pharmaceutical compositions and methods of using the same | 07 Feb, 2037 | Active |
US10987347 | Pharmaceutical compositions and methods of using the same | 07 Feb, 2037 | Active |
US11040032 | Pharmaceutical compositions and methods of using the same | 07 Feb, 2037 | Active |
US9867815 | Pharmaceutical compositions and methods of using the same | 07 Feb, 2037 | Active |
US8618172 | Galenical formulations of organic compounds | 13 Jul, 2028 | Active |
US8617595 | Galenic formulations of organic compounds | 19 Aug, 2026 | Active |
US8617595 | Galenic formulations of organic compounds | 19 Feb, 2026 | Active |
US9023893 | Synergistic combinations comprising a renin inhibitor for cardiovascular diseases | 03 Mar, 2022 | Expired |
US5559111 | δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides | 21 Jan, 2019 | Expired |
US5559111 | δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides | 21 Jul, 2018 | Expired |
Latest Legal Activities on Noden Pharma's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Noden Pharma.
Activity | Date | Patent Number |
---|---|---|
Payment of Maintenance Fee, 4th Year, Large Entity | 03 Jul, 2024 | US10894012 |
Payment of Maintenance Fee, 4th Year, Large Entity | 22 May, 2024 | US10857095 |
Expire Patent
Critical
| 12 Jun, 2023 | US9023893 |
Payment of Maintenance Fee, 4th Year, Large Entity | 08 Mar, 2023 | US10420760 (Litigated) |
Payment of Maintenance Fee, 4th Year, Large Entity | 01 Mar, 2023 | US10413505 |
Maintenance Fee Reminder Mailed
Critical
| 26 Dec, 2022 | US9023893 |
Payment of Maintenance Fee, 4th Year, Large Entity | 14 Sep, 2022 | US10231961 |
Payment of Maintenance Fee, 4th Year, Large Entity | 13 Jun, 2022 | US10016407 (Litigated) |
Surcharge for Late Payment, Large Entity | 13 Jun, 2022 | US10016407 (Litigated) |
Payment of Maintenance Fee, 4th Year, Large Entity | 09 Jun, 2022 | US10149843 |
Maintenance Fee Reminder Mailed
Critical
| 28 Feb, 2022 | US10016407 (Litigated) |
Payment of Maintenance Fee, 4th Year, Large Entity | 14 Jan, 2022 | US9867815 (Litigated) |
Surcharge for Late Payment, Large Entity | 14 Jan, 2022 | US9867815 (Litigated) |
Maintenance Fee Reminder Mailed
Critical
| 06 Sep, 2021 | US9867815 (Litigated) |
Patent Issue Date Used in PTA Calculation
Critical
| 22 Jun, 2021 | US11040032 |
Noden Pharma Drug Patents' Oppositions Filed in EPO
Noden Pharma drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Feb 04, 2009, by Teva Pharmaceuticals Industries Ltd.. This opposition was filed on patent number EP05015603A. Click below to reveal the latest opposition data.
Application | Filing Date | Opposition Party | Legal Status |
---|---|---|---|
EP08002401A | Apr, 2014 | STADA Arzneimittel AG | Revoked |
EP05015603A | Mar, 2009 | Ratiopharm GmbH | Revoked |
EP05015603A | Feb, 2009 | TEVA PHARMACEUTICALS INDUSTRIES LTD. | Revoked |
Noden Pharma's Family Patents
Noden Pharma Drug List
Given below is the complete list of Noden Pharma's drugs and the patents protecting them.
1. Goprelto
Goprelto is protected by 12 patents, out of which none have expired yet. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US10016407 | Pharmaceutical compositions and methods of using the same |
07 Feb, 2037
(12 years from now)
| Active |
US10149843 | Pharmaceutical compositions and methods of using the same |
07 Feb, 2037
(12 years from now)
| Active |
US10231961 | Pharmaceutical compositions and methods of using the same |
07 Feb, 2037
(12 years from now)
| Active |
US10413505 | Pharmaceutical compositions and methods of using the same |
07 Feb, 2037
(12 years from now)
| Active |
US10420760 | Pharmaceutical compositions and methods of using the same |
07 Feb, 2037
(12 years from now)
| Active |
US10857095 | Pharmaceutical compositions and methods of using the same |
07 Feb, 2037
(12 years from now)
| Active |
US10894012 | Pharmaceutical compositions and methods of using the same |
07 Feb, 2037
(12 years from now)
| Active |
US10933060 | Pharmaceutical compositions and methods of using the same |
07 Feb, 2037
(12 years from now)
| Active |
US10973811 | Pharmaceutical compositions and methods of using the same |
07 Feb, 2037
(12 years from now)
| Active |
US10987347 | Pharmaceutical compositions and methods of using the same |
07 Feb, 2037
(12 years from now)
| Active |
US11040032 | Pharmaceutical compositions and methods of using the same |
07 Feb, 2037
(12 years from now)
| Active |
US9867815 | Pharmaceutical compositions and methods of using the same |
07 Feb, 2037
(12 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Goprelto's drug page
2. Tekturna
Tekturna is protected by 4 patents, out of which 2 have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US8617595
(Pediatric)
| Galenic formulations of organic compounds |
19 Aug, 2026
(1 year, 10 months from now)
| Active |
US8617595 | Galenic formulations of organic compounds |
19 Feb, 2026
(1 year, 4 months from now)
| Active |
US5559111
(Pediatric)
| δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides |
21 Jan, 2019
(5 years ago)
| Expired |
US5559111 | δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides |
21 Jul, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tekturna's drug page
3. Tekturna Hct
Tekturna Hct is protected by 4 patents, out of which 3 have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US8618172 | Galenical formulations of organic compounds |
13 Jul, 2028
(3 years from now)
| Active |
US9023893 | Synergistic combinations comprising a renin inhibitor for cardiovascular diseases |
03 Mar, 2022
(2 years ago)
| Expired |
US5559111
(Pediatric)
| δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides |
21 Jan, 2019
(5 years ago)
| Expired |
US5559111 | δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides |
21 Jul, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tekturna Hct's drug page